Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
Completed · Phase 1
Conditions studied: Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
In brief
To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
Key facts
- Study ID
- NCT00543075
- Run by
- Genta Incorporated
- People needed
- 23
- Starts
- 2006-05-01
- Expected to finish
- 2009-09-01
- Last updated by the study team
- 2012-03-13
Who can join
Age: 0 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- DaVita Clinical Research — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.